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The role of vasoactive compounds, growth factors and cyto- stages. In both humans and animals with chronic renal
kines in the progression of renal disease. A number of kidney disease, the evolution of glomerulosclerosis is character-
diseases, and their progression to end-stage renal disease, are ized by progressive involvement of segments within indi-driven, in part, by the effects of angiotensin II. Increasing levels
vidual glomeruli and a decrease in the number of glomer-of angiotensin II may in turn up-regulate the expression of
uli and by the simplification and obliteration of tubulargrowth factors and cytokines, such as transforming growth
factor-b1 (TGF-b1), tumor necrosis factor-a (TNF-a), osteo- structures. Impairment of glomerular and tubular func-
pontin, vascular cell adhesion molecule-1 (VCAM-1), nuclear tion correlates with histologic changes. In the early stages
factor-kB (NF-kB), platelet-derived growth factor (PDGF), of glomerulosclerosis, proteinuria develops and is typi-basic fibroblast growth factor (bFGF) and insulin-like growth
cally followed by reductions in glomerular filtration ratefactor. Most of these compounds promote cell growth and
(GFR) and renal blood flow. Tubular atrophy is mani-fibrosis. Angiotensin II also stimulates oxidative stress. This
stress in turn may potentiate the vasoconstrictor effect of the fested by a progressive impairment of the kidneys’ capac-
peptide due, in part, to increased catabolism of nitric oxide ity to concentrate the urine or excrete acid.
(NO). Oxidative stress, fueled in part by angiotensin II, up-
regulates the expression of adhesion molecules, chemoattrac-
tant compounds and cytokines. The angiotensinogen gene, VASOACTIVE COMPOUNDSwhich provides the precursor for angiotensin production, is
stimulated by NF-kB activation. NF-kB is activated by angio- Angiotensin
tensin in the liver and in the kidney. This provides an autocrine A number of kidney diseases, and their progression toreinforcing loop that up-regulates angiotensin production. An-
end-stage renal failure, are driven by the intercrine, auto-giotensin II activates NF-kB through both AT1 and AT2 recep-
crine, paracrine and endocrine effects of angiotensin IItors. In addition, angiotensin-converting enzyme (ACE) inhibi-
tion markedly decreases NF-kB activation in the setting of (Ang II). All the components of the renin-angiotensin
renal disease. system (RAS), including substrate (angiotensinogen),
enzymes involved in the synthesis and degradation of
angiotensins, as well as receptors for angiotensins, are
Most forms of progressive renal disease lead to a com- present in the kidney. The intrarenal concentration of
mon histologic end point: the end-stage kidney, which Ang II is about one thousand-fold greater than the circu-
is usually fibrotic and reduced in mass [1]. The glomeruli lating levels of Ang II. Increasing levels of Ang II may
have a loss of capillaries and exhibit localized areas of in turn up-regulate the expression of other factors such
cell proliferation and progressive scarring that eventually transforming growth factor-b1 (TGF-b1), tumor necrosis
causes the capillary bed to collapse. Tubules, particularly factor-a (TNF-a), osteopontin, vascular cell adhesion
those attached to scarred glomeruli, are atrophied and molecule-1 (VCAM-1) and nuclear factor-kB (NF-kB),
often surrounded by inflammatory cells. There is diffused among others [2].
fibrosis characterized by increased deposition of collagen Ang II, the primary effector of the renin-angiotensin
and in the extracellular matrix, greater lipid deposition system, is produced both systemically and locally in vari-
and increased numbers of fibroblasts. On electron micro- ous tissues, including the heart and in blood vessel walls.
graphs, the tubular and glomerular basement membranes Ang II binds to two high-affinity receptors, designated
are often thickened in the early stages of the disease and the Ang II type-1 (AT1) receptor and the Ang II type-2
are condensed to an amorphous material in the later receptor (AT2). Signaling through the AT1 receptor re-
sults in vasoconstriction, stimulation of growth, and acti-
vation of fibroblasts and myocytes. Signaling through theKey words: Angiotensin II, tumor growth factor-b, tumor necrosis
factor-a, nuclear factor kB. AT2 receptor results in vasodilatation and antiprolifera-
tive responses, as well as an increase in apoptosis. ItÓ 2000 by the International Society of Nephrology
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appears therefore that most of the damaging effects of ane A2, and prostaglandin) are also up-regulated during
the course of progressive chronic renal disease. TheirAng II are mediated by the AT1 receptor [3].
Recent evidence indicates that Ang II increases the role in the pathophysiology of renal insufficiency, when
compared to Ang II, is not well understood.proliferation of vascular smooth muscle cells. The AT1
receptor for Ang II mediates the induction of cell growth.
Ang II increases the expression of several proliferative
GROWTH FACTORS
factors, including platelet-derived growth factor (PDGF),
Transforming growth factor-band basic fibroblast growth factor (bFGF). Ang II also
up-regulates TGF-b and insulin-like growth factor. Most Transforming growth factor-b (TGF-b) is a potent
fibrogenic factor. TGF-b has a role in embryonic devel-of these compounds promote cell growth and fibrosis.
Ang II also stimulates oxidative stress [4]. Such a stress opment and in regulating normal repair and regeneration
after tissue injury [9]. TGF-b is also a key element inpotentiates the vasoconstrictor role of the peptide be-
cause of increased catabolism of nitric oxide (NO). Also, the regulation of Ang II-induced hypertrophy of smooth
muscle cells [10]. In addition, TGF-b modulates the fibro-the generation of reactive oxygen species by Ang II may
promote atherogenesis by diverse mechanisms, including genic actions of bFGF and PDGF. Administration of an
ACE inhibitor in an animal model of ureteral obstructionoxidation of low-density lipoprotein (LDL) cholesterol.
Pharmacological blockade of the AT1 receptor reverses decreased the expression of TGF-b and collagen and
ameliorated the degree of interstitial fibrosis [11]. It isendothelial dysfunction and catabolism of NO leading
to attenuation of atherosclerosis. Oxidative stress, fueled likely that ACE inhibitors decrease renal tubulointersti-
tial fibrosis by down-regulating TGF-b synthesis inducedin part by Ang II, up-regulates the expression of adhesion
molecules, chemoattractant compounds and cytokines. by Ang II.
TGF-b stimulates the synthesis of matrix proteins (fi-The angiotensinogen gene, which provides the precursor
for angiotensin production, is stimulated by NF-kB activa- bronectin, laminin and collagens) and decreases matrix
degradation by increasing the activity of protease inhibi-tion [5–7]. Interestingly NF-kB is activated by Ang II in
the liver [6, 7] and in the kidney [8]. This provides an tors and also by intrinsically decreasing the amount of the
proteases. TGF-b also stimulates the synthesis of matrixautocrine reinforcing loop that up-regulates Ang II pro-
duction. We found that Ang II activates NF-kB through protein receptors such as integrins and osteopontin.
TGF-b increases osteopontin production by the kidney,both AT1 and AT2 receptors [2]. In addition angioten-
sin-converting enzyme (ACE) inhibition markedly de- decreases the half-life of the osteopontin message, and
increases osteopontin secretion.creases NF-kB activation in the kidney in the setting of
renal disease [8]. TGF-b is secreted in an inactive (latent) form that
requires processing before it can exert its effect. LatentWe also found that nuclear extracts obtained from the
cortex of kidneys with ureteral obstruction contained TGF-b is stored at the surface of cells and the extracellu-
lar matrix (ECM) where it is converted to active TGF-b,proteins that bind to an NF-kB-like sequence contained
in the rat TNF-a gene promoter [2]. These proteins are by mechanisms not completely understood [12, 13]. Ac-
tive TGF-b is a 25-kD protein composed of two subunitsnot present in nuclear extracts prepared from the cortex
of the contralateral kidney or kidneys of sham-operated linked by a disulfide bond. Five distinct isoforms of TGF-b
have been identified and three of these, TGF-b1, TGF-b2animals. We found that ACE inhibition decreased the
amount of NF-kB binding proteins within the nuclear and TGF-b3 are found in all mammalian species.
A potential scenario by which TGF-b affects the pro-extract at four hours but not at longer intervals of time.
TNF-a itself stimulates NF-kB activation [7], which cre- gression of renal disease may be as follows: thrombo-
spondin (TSP1) activates latent TGF-b in tissues, Ang IIates an autocrine reinforcing loop for enhanced TNF-a
formation (Fig. 1). Because, the NF-kB family of tran- up-regulates TGF-b and TSP1 [14, 15] and TSP1 pre-
cedes and predicts the presence of renal fibrosis [16].scription factors have many potential combinations, it is
possible that different NF-kB isotypes are activated by Activation of TGF-b further stimulates endothelin pro-
duction [17]. Endothelin, in turn, is also a potent stimulusAng II at different phases of the progression of renal
disease. Angiotensin II stimulates NF-kB activation, for glomerulosclerosis and fibrogenesis [18].
Local production of TGF-b, by intrinsic renal cellsleading to increased TNF-a synthesis which in turn can
activate further NF-kB. The 40% diminution in TNF-a or by macrophages invading the kidney, may be a key
mediator of renal fibrosis. However, circulating TGF-bmRNA expression observed with ACE inhibition in rats
with renal disease may be attributable to the blunting of may have also an important role in pathophysiologic
processes. Increased hepatic production of TGF-b ina subset of NF-kB homodimers or heterodimers. Other
subsets of NF-kB dimers may perpetuate NF-kB induc- transgenic mice leads to liver fibrosis, myocarditis and
renal disease [16]. In this model, increased circulatingtion causing eventual escape from ACE inhibition.
Other vasoactive compounds (endothelin, thrombox- levels of TGF-b induced renal disease characterized by
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Fig. 1. Role of angiotensin II in the progres-
sion of chronic renal disease.
accumulation of matrix proteins, interstitial fibrosis and Platelet-derived growth factor-b
mesangial expansion. It was shown that PDGF-stimulated synthesis of fi-
TGF-b affects diverse proteins present in the extracel- bronectin and type III collagen is mediated by increased
lular matrix, including collagen types I, II, III, IV, and TGF-b production [24, 25]. Several studies indicate auto-
V, fibronectin, osteopontin, thrombospondin, tenacin, crine and paracrine interactions between PDGF and
elastin, hyaluronic acid, osteonectin, SPARC and pro- TGF-b. Also, PDGF stimulates TGF-b mRNA and its
teoglycans (biglycan and decorin). TGF-b inhibits matrix protein in rat kidney fibroblasts, mouse macrophages and
degradation by increasing the activity of tissue inhibitors human renal proximal tubular cells [24–26]. Antibodies
of metalloproteinases (TIMP) and by decreasing the ac-
against PDGF prevent the increase in gene expressiontivity of metalloproteinase. It also stimulates the synthe-
and protein synthesis of TGF-b elicited by high glucosesis of receptors for ECM proteins (Fig. 2). Furthermore,
concentrations in proximal tubular cells [27].TGF-b is a chemoattractant for fibroblasts [9] and stimu-
Up-regulation of mRNAs encoding the PDGF-b chainlates fibroblast proliferation [19]. Thus, this cytokine has
and the corresponding PDGF-b receptor has been re-a major role in the accumulation of ECM protein in the
ported in glomeruli from diabetic rats, as well as in mes-renal interstitium. This includes fibroblast proliferation
angial cells exposed in culture to high glucose mediumand the subsequent stimulation of ECM protein produc-
[28–30]. Since expression of PDGF-b coincides with mes-tion by fibroblasts and tubule epithelial cells.
angial cell proliferation [28], it is likely that this potentTGF-b also plays a pivotal role in the development
mitogen stimulates early mitosis of glomerular cells withof renal hypertrophy and accumulation of ECM compo-
subsequent induction of TGF-b, which, in turn, inhibitsnents in diabetes mellitus [20, 21]. Increased expression
proliferation, stimulates hypertrophy, and increases col-of TGF-b occurs in vivo in experimentally induced diabe-
tes as well as in patients with diabetes [22, 23]. lagen production [31].
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Fig. 2. Pathogenesis of interstitial fibrosis. Abbreviations are: ECM, extracellular matrix; TGF-b1, transforming growth factor-b1; ", increase; #,
decrease.
Hepatocyte growth factor This protective effect of HGF appears to involve a sup-
pression of renal epithelial cell apoptosis [36].Recent studies showed that expression of hepatocyte
growth factor (HGF), a major effector mediating regen- Insulin-like growth factor-I
erative liver and kidney growth subsequent to injury.
Several studies suggest that insulin-like growth factor-IBoth HGF and its tyrosine kinase receptor, the protein
(IGF-I) is involved in diabetic renal growth [37, 38].product of the c-met oncogene, are both up-regulated
Renal IGF-I protein level is elevated during the earlyin the kidney of diabetic rats [32]. Immunohistochemistry
phase of development of renal growth in experimentallyshowed an increase of c-met protein in tubular cells, espe-
induced diabetes [37]. This increase in renal IGF-I con-
cially in the distal tubule [32]. In addition, high-glucose
tent is not associated with elevated circulating levels of
medium mimics the induction of HGF in cultured proxi- growth hormone or IGF-I [39]. Also the expression of
mal tubular and inner medullary collecting duct cells IGF-I receptor mRNA and total binding of IGF-I to its
[32]. On the other hand, cultured aortic endothelial cells receptor are both increased 2 weeks after induction of
exposed to high-glucose media express less HGF than diabetes [38]. In situ hybridization studies showed that
cells exposed to normal-glucose media [33]. The signifi- the increase in IGF-I receptor mRNA expression in dia-
cance of these findings is not currently clear; neutraliza- betic rats is principally localized to glomerular endothe-
tion or inhibitor studies will be required to define the lial and mesangial cells, as well as collecting ducts [40].
exact role that HGF may play during kidney hypertrophy Long-term treatment of diabetic rats with the somato-
in the setting of diabetes. statin analog octreotide (which antagonizes release of
The c-met gene product is induced by a variety of growth hormone and therefore lowers tissue IGF-I lev-
growth factors such as TGF-b, PDGF, IGF-I and HGF els) reduces the increase in kidney weight [41]. However,
itself [34]. A reinforcing mechanism of HGF and c-met because IGF-I is clearly a mitogen for cultured mesangial
induction is thought to play a role in restoring tubule cells [42] and proximal tubular cells [43], IGF-I accumu-
function and integrity after renal injury [34]. HGF pro- lation in the kidney probably represents a more permis-
sive general factor for maintenance of adequate renalmotes recovery from acute ischemic renal injury [35].
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growth rather than a specific factor for the induction of interstitial injury in the obstructed kidney. Leukocytes,
infiltrating the renal interstitium of the obstructed kid-diabetic renal hypertrophy.
ney, do not appear to contribute to the increased expres-
sion of TNF-a mRNA. Angiotensin II appears to con-
CYTOKINES
tribute, at least in part, to the early increase in expression
Tumor necrosis factor-a of TNF-a mRNA in the obstructed kidney.
TNF-a has a role in the recruitment of inflammatoryActivation of the human TNF-a gene leads to the
production of a protein with 233 amino acids. The signal cells in animal models of glomerular injury. It stimulates
the production of chemotactic factors by resident cellssequence of full-length TNF-a is unusually long (76 amino
acids). This signal sequence provides a mechanism by and up-regulates MCP-1 mRNA in human mesangial
cells. Wolf et al [49] found that TNF-a increaseswhich TNF-a can exist as an integral membrane protein,
with the carboxy-terminus extracellular. Mature TNF-a RANTES mRNA in a murine mesangial cell line and in
vivo in rat kidneys perfused with TNF-a. Mulligan et alconsists of 157 amino acids with a molecular mass of 17
kD. Fully mature TNF-a proteins self-assemble as homo- [50] reported that anti-TNF-a or soluble recombinant
human TNFR1 blocked the up-regulation of intercellulartrimers with masses of 51 kD. The macrophage is one
of the major sources of TNF-a, but TNF-a is also pro- adhesion molecule-1 (ICAM-1), endothelial leukocyte
adhesion molecule-1 (ELAM-1), and vascular adhesionduced by resident renal cells [44, 45]. Two TNF-a re-
ceptors have been described: one with a molecular weight molecule-1 (VCAM-1) in nephrotoxic nephritis. The
above data support the concept that TNF-a contributesof 55 kD (TNFR1) and the other with a molecular weight
of 75 kD (TNFR2) [46]. Binding of TNF-a to its receptors to the increased macrophage migration into the renal
interstitium of the affected kidney. An early increase inactivates a number of signal transduction pathways that
result in the expression of a variety of transcription fac- TNF-a in the kidney up-regulates the production of a
chemoattractant(s) for monocytes and contributes to thetors, cytokines, growth factors, receptors, cell adhesion
molecules, mediators of inflammatory processes, acute infiltration of the obstructed kidney by leukocytes.
phase proteins, and major histocompatibility complex The binding of TNF-a to a cell surface receptor results
proteins [46]. Lipopolysaccharide (LPS)-induced renal in intracellular metabolic changes that mediate apoptotic
injury is associated with increased expression of TNF-a and necrotic cell death [51, 52]. Although the mechanism
by renal cells. Proximal tubular cells express TNF-a of the cytocidal action of TNF-a has not been completely
when stimulated with interleukin-1a or LPS [47]. Also, elucidated, the TNFR1 receptor has been shown to have
mRNA transcripts of TNF-a are found in cortical tubules a cytoplasmic domain sequence similar to the Fas antigen
of mice injected with LPS. Thus, resident renal cells receptor, which is considered to mediate apoptosis [53].
(glomerular mesangial cells and tubular epithelial cells)
are sources of TNF-a production in renal injury. We
NUCLEAR FACTOR-kBfound [48] that in normal rats TNF-a mRNA was more
Nuclear factor-kB (NF-kB) has a role in the transcrip-abundant in glomeruli than in renal cortical tubules. We
tional regulation of a number of genes in several tissues,measured TNF-a mRNA in the renal cortex of rats at
including the kidney [54]. NF-kB is located in the celldifferent times after the onset of unilateral ureteral ob-
cytoplasm in an inactive form, complexed to an inhibitorstruction and determined whether Ang II inhibition or
(IkB). The activated form of NF-kB is a homodimer ortotal body irradiation affected the mRNA levels of TNF-a
heterodimer, composed of two proteins that are mem-[48]. Cortical tubules obtained from the kidney with ure-
bers of the NF-kB family. These family members are p50,teral obstruction had a marked increase in TNF-a mRNA
p52, p65 (relA), relB, and c-rel [55]. Certain compoundsexpression, whereas the glomeruli obtained from the same
(TNF-kB), lipopolysaccharide (LPS) or phorbol myris-kidneys did not. Thus, up-regulation of TNF-a expres-
tate acetate (PMA) induce the dissociation of the NF-sion was confined to renal tubular cells of the obstructed
kBaIkB complex, with subsequent translocation of NF-kBkidney. Administration of enalapril, an ACE inhibitor,
to the nucleus. NF-kB in the nucleus binds to DNAbefore and during unilateral ureteral obstruction de-
motifs present in the promoter of various genes, particu-creased TNF-a mRNA levels in the obstructed kidney
larly those associated with an inflammatory or immuneby about 40% at 4 hours after the onset of obstruction.
response [55]. NF-kB is activated during experimentalHowever, at 120 hours there was no difference in TNF-a
ureteral obstruction [8, 56]. Administration of an ACElevels between the obstructed kidneys of rats given or not
inhibitor, enalapril, significantly decreased the activationgiven an ACE inhibitor. Total body irradiation, which
of NF-kB in the kidney with ureteral ligation [8]. It hasprevents the migration of macrophages to the obstructed
been reported recently that interleukin-10 (IL-10) andkidney, did not affect the up-regulation of TNF-a mRNA
IL-13 suppress NF-kB activation presumably throughexpression at 4 hours after unilateral ureteral obstruc-
tion. Thus, TNF-a may have a role in initiating tubulo- preservation of IkB [57]. Transcription factors of the
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NF-kB family can influence directly or indirectly cellular secondary beneficial effect occurs through a modest in-
crease in nitric oxide generation due to the elevatedevents leading to tissue fibrosis. As discussed previously,
kinin levels. Nitric oxide generation in this context isthe profibrotic cytokine TGF-b1 has a major role in
beneficial at ameliorating the tubulointerstitial fibrosismatrix protein overproduction in a wide variety of kidney
of obstructive nephropathy [67].diseases [21]. The gene promoter for TGF-b1 is not con-
trolled by NF-kB; however, the tissue enzyme transglu-
Reprint requests to Saulo Klahr, M.D., Simon Professor of Medicine,
taminase is an activator of latent TGF-b1 and the pro- Department of Medicine, Washington University School of Medicine,
Barnes-Jewish Hospital, 216 S. Kingshighway Boulevard, St. Louis,moter of transglutaminase is regulated by NF-kB [58].
MO 63110-1092, USA.Tissue transglutaminase cleaves osteopontin [59], which
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is a protein expressed by tubular epithelial cells of the
kidney in several disease models including obstructive
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